Sunday, July 22, 2018
Company News: Page (1) of 1 - 06/29/18 Email this story to a friend. email article Print this page (Article printing at page facebook
Joylux, Inc. and Consortia Health Form Alliance to Strengthen Access to Intimate Health Solutions
Two female-founded companies joining forces to stop the taboo behind sexual health
(June 29, 2018)

SEATTLE, June 29, 2018 /PRNewswire/ -- Joylux, Inc., the leading Femtech device company, announced today that it is partnering with Consortia Health, the largest US pelvic-floor health service provider operating in 30 states. Consortia will offer its patients vFit PLUS to help enhance vaginal wellness and improve sexual function post Consortia's training program. vFit PLUS is the world's first patented home-use feminine rejuvenation device using red-light (LED) technology.

Colette Courtion, Joylux CEO, said, "This is a perfect match. We are both leaders in our space. Together we can raise awareness about this taboo topic and improve the quality of life for many women. Everyone benefits from this alliance- a win for patients, Consortia, and Joylux."

With more than 100,000 patient sessions, Consortia Health's staff of registered nurses, nurse practitioners, and nurse midwives has provided services in 30 states, benefiting women through physician-centered, in-clinic training programs that strengthen pelvic floor muscles and improve sensation. The protocols significantly help women with symptoms of pelvic floor dysfunction, which can include urinary and fecal incontinence and sexual function concerns.

Jeff Oliva, Consortia CEO, said, "Our clinical team typically offers patients at-home care products for post-treatment maintenance. We have not seen anything like vFit PLUS and its innovative technology. vFit PLUS will help us expand our solution offering to address sexual health, which is part of living a full life. Our patients want a trusted product that is safe, simple, and easy to use while delivering great results—that's what they will get with vFit PLUS."

Both companies received investment from Golden Seeds, an early-stage investing organization with a focus on women-led businesses. Jackie Magno and Laura Baldwin, deal leads, added, "We invested in both companies because pelvic floor health is an underserved market and both companies play a vital role in solving these common issues. The synergy they create together can be transformative in women's health."

About Joylux, Inc.
Joylux, Inc. is a global women's health technology company creating innovative medical and feminine wellness devices under the vSculpt and vFit brands.

About Consortia Health
Consortia Health is a personalized pelvic wellness health care company that provides clinically-relevant individualized diagnosis, therapy, medical products and devices with education to help patients with pelvic floor dysfunction.

Heather Dazell
[email protected]


Cision View original content:

SOURCE Joylux, Inc.

Copyright 2014 PR Newswire. All Rights Reserved

Page: 1

Related Keywords: Inc.,Surgery,Nurse,Science,Medical,Women,
Related Sites: DMN Newswire ,   HTN - Health Technology Net
Related Newsletter: Tutorial Finder ,   Review Seeker ,   DMN Newswire Newsletter

  • Healthcare IT Market 2018 - 2023 with SWOT Analysis regarding upcoming Changes and Technology Adaptations in Global Healthcare Sector
  • Vision Care Product Market To Witness Enhanced Growth Owing To Rising Occurrence Of Eye Disorders Till 2021 | Million Insights
  • Global Prosthetic Heart Valve Market Reaching at a CAGR of +12.70% by Geography, Deployment Model, Component, and Key players are Boston Scientific Cardiology, CryoLife, Inc., Abbott
  • Trauma Fixation Global Market to Register Steady Expansion During 2018-2025
  • Global Surgical Apparel Market Will Reach USD 2,966.58 million by 2024: Zion Market Research

  • BeiGene Announces Plan to Pursue Accelerated Approval in the U.S. of BTK Inhibitor Zanubrutinib in Waldenström Macroglobulinemia (WM)
  • HedgePath Pharmaceuticals Granted Exclusive Option to License UCONN's Patented Chemical Analogues of Itraconazole
  • Alligator Bioscience Submits Application to Start Clinical Phase I Study in Cancer Patients with ATOR-1015, a Unique CTLA-4 and OX40 Binding Antibody
  • Yisheng Biopharma Announces Opening of New Business Divisions in Cambodia, Expanding Presence within Southeast Asia

    Our Privacy Policy --- About The Health Technology - Contact Us - Advertise With Us - Privacy Guidelines